These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 22591635)
1. SOCS3 in immune regulation of inflammatory bowel disease and inflammatory bowel disease-related cancer. Li Y; de Haar C; Peppelenbosch MP; van der Woude CJ Cytokine Growth Factor Rev; 2012 Jun; 23(3):127-38. PubMed ID: 22591635 [TBL] [Abstract][Full Text] [Related]
2. SOCS3 and STAT3, major controllers of the outcome of infection with Mycobacterium tuberculosis. Rottenberg ME; Carow B Semin Immunol; 2014 Dec; 26(6):518-32. PubMed ID: 25458989 [TBL] [Abstract][Full Text] [Related]
3. Dysregulation of IL6/IL6R-STAT3-SOCS3 signaling pathway in IBD-associated colorectal dysplastic lesions as compared to sporadic colorectal adenomas in non-IBD patients. Gui X; Iacucci M; Ghosh S Pathol Res Pract; 2020 Nov; 216(11):153211. PubMed ID: 32979687 [TBL] [Abstract][Full Text] [Related]
4. Interleukin-10 anti-inflammatory response to Borrelia burgdorferi, the agent of Lyme disease: a possible role for suppressors of cytokine signaling 1 and 3. Dennis VA; Jefferson A; Singh SR; Ganapamo F; Philipp MT Infect Immun; 2006 Oct; 74(10):5780-9. PubMed ID: 16988256 [TBL] [Abstract][Full Text] [Related]
5. Suppressors of cytokine signaling and immunity. Kubo M; Hanada T; Yoshimura A Nat Immunol; 2003 Dec; 4(12):1169-76. PubMed ID: 14639467 [TBL] [Abstract][Full Text] [Related]
6. Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease. Andoh A; Shioya M; Nishida A; Bamba S; Tsujikawa T; Kim-Mitsuyama S; Fujiyama Y J Immunol; 2009 Jul; 183(1):687-95. PubMed ID: 19535621 [TBL] [Abstract][Full Text] [Related]
7. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Li Y; de Haar C; Chen M; Deuring J; Gerrits MM; Smits R; Xia B; Kuipers EJ; van der Woude CJ Gut; 2010 Feb; 59(2):227-35. PubMed ID: 19926618 [TBL] [Abstract][Full Text] [Related]
8. IL-21 enhances SOCS gene expression and inhibits LPS-induced cytokine production in human monocyte-derived dendritic cells. Strengell M; Lehtonen A; Matikainen S; Julkunen I J Leukoc Biol; 2006 Jun; 79(6):1279-85. PubMed ID: 16551679 [TBL] [Abstract][Full Text] [Related]
9. The innate immune system and inflammatory bowel disease. Davies JM; Abreu MT Scand J Gastroenterol; 2015 Jan; 50(1):24-33. PubMed ID: 25523553 [TBL] [Abstract][Full Text] [Related]
10. SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. Wong PK; Egan PJ; Croker BA; O'Donnell K; Sims NA; Drake S; Kiu H; McManus EJ; Alexander WS; Roberts AW; Wicks IP J Clin Invest; 2006 Jun; 116(6):1571-81. PubMed ID: 16710471 [TBL] [Abstract][Full Text] [Related]
11. Suppressors of cytokine signaling 3 is essential for FcγR-mediated inflammatory response via enhancing CCAAT/enhancer-binding protein δ transcriptional activity in macrophages. Yan C; Liu Y; Gao H; Wang X Exp Cell Res; 2015 Sep; 337(1):120-7. PubMed ID: 26209606 [TBL] [Abstract][Full Text] [Related]
12. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development. Waldner MJ; Neurath MF Semin Immunol; 2014 Feb; 26(1):75-9. PubMed ID: 24447345 [TBL] [Abstract][Full Text] [Related]
13. Interleukin 11 signaling components signal transducer and activator of transcription 3 (STAT3) and suppressor of cytokine signaling 3 (SOCS3) regulate human endometrial stromal cell differentiation. Dimitriadis E; Stoikos C; Tan YL; Salamonsen LA Endocrinology; 2006 Aug; 147(8):3809-17. PubMed ID: 16709613 [TBL] [Abstract][Full Text] [Related]
14. Cells of the innate and adaptive immunity and their interactions in inflammatory bowel disease. Kmieć Z; Cyman M; Ślebioda TJ Adv Med Sci; 2017 Mar; 62(1):1-16. PubMed ID: 28126697 [TBL] [Abstract][Full Text] [Related]
16. Suppressor of cytokine signalling-3 at pathological levels does not regulate lipopolysaccharide or interleukin-10 control of tumour necrosis factor-alpha production by human monocytes. Prêle CM; Keith-Magee AL; Yerkovich ST; Murcha M; Hart PH Immunology; 2006 Sep; 119(1):8-17. PubMed ID: 16925527 [TBL] [Abstract][Full Text] [Related]
17. Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3. Tamiya T; Kashiwagi I; Takahashi R; Yasukawa H; Yoshimura A Arterioscler Thromb Vasc Biol; 2011 May; 31(5):980-5. PubMed ID: 21508344 [TBL] [Abstract][Full Text] [Related]
18. Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon. Rigby RJ; Simmons JG; Greenhalgh CJ; Alexander WS; Lund PK Oncogene; 2007 Jul; 26(33):4833-41. PubMed ID: 17297444 [TBL] [Abstract][Full Text] [Related]
19. Development and Function of Immune Cells in an Adolescent Patient With a Deficiency in the Interleukin-10 Receptor. Veenbergen S; van Leeuwen MA; Driessen GJ; Kersseboom R; de Ruiter LF; Raatgeep RHC; Lindenbergh-Kortleve DJ; Simons-Oosterhuis Y; Biermann K; Halley DJJ; de Ridder L; Escher JC; Samsom JN J Pediatr Gastroenterol Nutr; 2017 Jul; 65(1):e5-e15. PubMed ID: 28644354 [TBL] [Abstract][Full Text] [Related]
20. Innate immunity in inflammatory bowel disease: state of the art. Hisamatsu T; Ogata H; Hibi T Curr Opin Gastroenterol; 2008 Jul; 24(4):448-54. PubMed ID: 18622158 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]